Articles producció científica> Enginyeria Electrònica, Elèctrica i Automàtica

Enzyme and Thermo Dual-Stimuli Responsive DOX Carrier Based on PNIPAM Conjugated Mesoporous Silica

  • Identification data

    Identifier: imarina:9282893
    Authors:
    Ebrahimi SMIradmousa MKRashed MFattahi YArdakani YHBahadorikhalili SBafkary RErfan MDinarvand RMahboubi A
    Abstract:
    Background: Stimuli-responsive drug delivery systems have been proven to be a promising strategy to enhance tumor localization, overcome multidrug resistance (MDR), and reduce the side effects of chemotherapy agents. Objectives: In this study, a temperature and redox dual stimuli-responsive system using mesoporous silica nanoparticles (MSNs) for targeted delivery of doxorubicin (DOX) was developed. Methods: Mesoporous silica nanoparticles were capped with poly(N-isopropylacrylamide) (PNIPAM), a thermo-sensitive polymer, with atom transfer radical polymerization (ATRP) method, via disulfide bonds (DOX-MSN-S-S-PNIPAM) to attain a controlled system that releases DOX under glutathione-rich (GSH-rich) environments and temperatures above PNIPAM’s lower critical solution temperature (LCST). Morphological and physicochemical properties of the nanoparticles were indicated using transmission electron microscopy (TEM), dynamic light scattering (DLS), energy-dispersive X-ray spectroscopy (EDS), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and Brunauer-Emmett-Teller (BET). The drug release tests were performed at 25°C and 41°C in the absence and presence of the DTT, and the obtained results confirmed the synergic effect of temperature and reductive agent on a dual responsive release profile with a 73% cumulative release at 41°C and reductive environment during 240 min. Results: The average loaded drug content and encapsulation efficacy were reported as 42% and 29.5% at the drug: nanoparticle ratio of 1.5: 1. In vitro cytotoxicity assays on MCF-7 cell lines indicated significant viability decreased in cells exposed to DOX-MSN-S-S-PNIPAM compared to the free drug (DOX). Conclusions: Based on the results, DOX-MSN-S-S-PNIPAM has shown much more efficiency w
  • Others:

    Author, as appears in the article.: Ebrahimi SM; Iradmousa MK; Rashed M; Fattahi Y; Ardakani YH; Bahadorikhalili S; Bafkary R; Erfan M; Dinarvand R; Mahboubi A
    Department: Enginyeria Electrònica, Elèctrica i Automàtica
    URV's Author/s: Bahadorikhalili, Saeed
    Keywords: Stimuli-responsive Nanoparticles Drug-delivery Drug delivery Cancer Atrp polymerization stimuli-responsive release reduction polymerization nanoparticles drug delivery doxorubicin core copolymer cancer
    Abstract: Background: Stimuli-responsive drug delivery systems have been proven to be a promising strategy to enhance tumor localization, overcome multidrug resistance (MDR), and reduce the side effects of chemotherapy agents. Objectives: In this study, a temperature and redox dual stimuli-responsive system using mesoporous silica nanoparticles (MSNs) for targeted delivery of doxorubicin (DOX) was developed. Methods: Mesoporous silica nanoparticles were capped with poly(N-isopropylacrylamide) (PNIPAM), a thermo-sensitive polymer, with atom transfer radical polymerization (ATRP) method, via disulfide bonds (DOX-MSN-S-S-PNIPAM) to attain a controlled system that releases DOX under glutathione-rich (GSH-rich) environments and temperatures above PNIPAM’s lower critical solution temperature (LCST). Morphological and physicochemical properties of the nanoparticles were indicated using transmission electron microscopy (TEM), dynamic light scattering (DLS), energy-dispersive X-ray spectroscopy (EDS), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and Brunauer-Emmett-Teller (BET). The drug release tests were performed at 25°C and 41°C in the absence and presence of the DTT, and the obtained results confirmed the synergic effect of temperature and reductive agent on a dual responsive release profile with a 73% cumulative release at 41°C and reductive environment during 240 min. Results: The average loaded drug content and encapsulation efficacy were reported as 42% and 29.5% at the drug: nanoparticle ratio of 1.5: 1. In vitro cytotoxicity assays on MCF-7 cell lines indicated significant viability decreased in cells exposed to DOX-MSN-S-S-PNIPAM compared to the free drug (DOX). Conclusions: Based on the results, DOX-MSN-S-S-PNIPAM has shown much more efficiency with stimuli-responsive properties in comparison to DOX on MCF-7 cancer cell lines.
    Thematic Areas: Pharmacology, toxicology and pharmaceutics (miscellaneous) Pharmacology, toxicology and pharmaceutics (all) Pharmacology (medical) Pharmacology & pharmacy General pharmacology, toxicology and pharmaceutics
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: saeed.bahadorikhalili@urv.cat
    Author identifier: 0000-0001-8047-342X
    Record's date: 2023-08-05
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://brieflands.com/articles/ijpr-130474.html
    Papper original source: Iranian Journal Of Pharmaceutical Research. 21 (1):
    APA: Ebrahimi SM; Iradmousa MK; Rashed M; Fattahi Y; Ardakani YH; Bahadorikhalili S; Bafkary R; Erfan M; Dinarvand R; Mahboubi A (2022). Enzyme and Thermo Dual-Stimuli Responsive DOX Carrier Based on PNIPAM Conjugated Mesoporous Silica. Iranian Journal Of Pharmaceutical Research, 21(1), -. DOI: 10.5812/ijpr-130474
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Article's DOI: 10.5812/ijpr-130474
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2022
    Publication Type: Journal Publications
  • Keywords:

    Pharmacology & Pharmacy,Pharmacology (Medical),Pharmacology, Toxicology and Pharmaceutics (Miscellaneous)
    Stimuli-responsive
    Nanoparticles
    Drug-delivery
    Drug delivery
    Cancer
    Atrp polymerization
    stimuli-responsive
    release
    reduction
    polymerization
    nanoparticles
    drug delivery
    doxorubicin
    core
    copolymer
    cancer
    Pharmacology, toxicology and pharmaceutics (miscellaneous)
    Pharmacology, toxicology and pharmaceutics (all)
    Pharmacology (medical)
    Pharmacology & pharmacy
    General pharmacology, toxicology and pharmaceutics
  • Documents:

  • Cerca a google

    Search to google scholar